1. Home
  2. SOTK vs MAIA Comparison

SOTK vs MAIA Comparison

Compare SOTK & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sono-Tek Corporation

SOTK

Sono-Tek Corporation

HOLD

Current Price

$4.73

Market Cap

72.1M

Sector

Technology

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.35

Market Cap

79.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOTK
MAIA
Founded
1975
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.1M
79.0M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
SOTK
MAIA
Price
$4.73
$1.35
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.5K
569.7K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
37.50
33.33
EPS
0.05
N/A
Revenue
$20,909,315.00
N/A
Revenue This Year
$4.02
N/A
Revenue Next Year
$10.95
N/A
P/E Ratio
$94.40
N/A
Revenue Growth
1.97
N/A
52 Week Low
$3.40
$0.87
52 Week High
$6.24
$3.19

Technical Indicators

Market Signals
Indicator
SOTK
MAIA
Relative Strength Index (RSI) 46.38 50.62
Support Level $3.81 $1.25
Resistance Level $4.75 $1.48
Average True Range (ATR) 0.29 0.07
MACD 0.01 0.00
Stochastic Oscillator 49.21 44.74

Price Performance

Historical Comparison
SOTK
MAIA

About SOTK Sono-Tek Corporation

Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: